Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

Note: The words woman/women/mother/she/her have been used throughout this guideline as most pregnant and birthing people identify with their birth sex. However, for the purpose of this guideline, these terms include people who do not identify as women or mothers, including those with a non-binary identity. All clinicians should ask the pregnant person what their preferred term is and ensure this is communicated to the healthcare team.

Explanation of the Aboriginal artwork:
The aboriginal artwork used symbolises the connection to country and the circle shape shows the strong relationships amongst families and the aboriginal culture. The horse shoe shape design shown in front of the generic statement symbolises a woman and those enclosing a smaller horse shoe shape depicts a pregnant women. The smaller horse shoe shape in this instance represents the unborn child. The artwork shown before the specific statements within the document symbolises a footprint and demonstrates the need to move forward together in unison.

Australian Aboriginal Culture is the oldest living culture in the world yet Aboriginal people continue to experience the poorest health outcomes when compared to non-Aboriginal Australians. In South Australia, Aboriginal women are 2-5 times more likely to die in childbirth and their babies are 2-3 times more likely to be of low birth weight. The accumulative effects of stress, low socio economic status, exposure to violence, historical trauma, culturally unsafe and discriminatory health services and health systems are all major contributors to the disparities in Aboriginal maternal and birthing outcomes. Despite these unacceptable statistics, the birth of an Aboriginal baby is a celebration of life and an important cultural event bringing family together in celebration, obligation and responsibility. The diversity between Aboriginal cultures, language and practices differ greatly and so it is imperative that perinatal services prepare to respectfully manage Aboriginal protocol and provide a culturally positive health care experience for Aboriginal people to ensure the best maternal, neonatal and child health outcomes.

Purpose and Scope of Perinatal Practice Guideline (PPG)
The purpose of this guideline is to provide clinicians with information on the antibiotic(s) to be used for prophylaxis in women during the peripartum period and also for treatment of specific sites of infection during this time. It includes information on the dosage, frequency and route of administration but does not include dilution and administration duration information. Refer to local hospital guidelines or the Australian Injectable Drugs Handbook.
Table of Contents

Purpose and Scope of Perinatal Practice Guideline (PPG) ............................................. 1
Summary of Practice Recommendations ................................................................. 3
Abbreviations ........................................................................................................... 3
Definitions ................................................................................................................ 4
Prophylactic Antibiotic Use in the Peripartum Period ............................................. 4
  Group B Streptococcus (Intrapartum prophylaxis) .............................................. 4
  Caesarean Section ................................................................................................. 5
Instrumental Vaginal Birth ...................................................................................... 5
Manual Removal of the Placenta ............................................................................ 6
3rd or 4th degree perineal tears .............................................................................. 6
Endocarditis Prophylaxis in Women with Cardiac Disease .................................. 7
Prelabour Rupture of Membranes ≥ 37 weeks (PROM) ......................................... 8
Preterm Prelabour Rupture of Membranes (PPROM) ............................................ 8
PPROM with no evidence of chorioamnionitis ....................................................... 8
PPROM with evidence of chorioamnionitis ............................................................ 8
Preterm Labour ....................................................................................................... 8
Antibiotic Treatment of Infection .......................................................................... 9
  Chorioamnionitis .................................................................................................. 9
Endometritis ........................................................................................................... 10
Mastitis .................................................................................................................... 11
Bacterial Vaginosis ................................................................................................. 11
Sepsis where source is unknown ........................................................................... 12
Urinary Tract Infection .......................................................................................... 12
Gentamicin use and dosing .................................................................................... 13
  Monitoring gentamicin levels .............................................................................. 13
References .............................................................................................................. 14
Useful Websites: ..................................................................................................... 14
Appendix 1 | Beta-lactam Assessment Tool ............................................................. 15
Appendix 2 | Reconstituting BenzylPenicillin .......................................................... 16
Acknowledgements ................................................................................................ 17
Summary of Practice Recommendations

Infection during pregnancy and the postpartum period may be caused by a combination of organisms, including aerobic and anaerobic cocci and bacilli. Prophylactic antibiotics and standard infection prevention practices can reduce the risk of postpartum infectious morbidity.

When women with penicillin and cephalosporin allergy are screened for GBS during pregnancy, culture and sensitivity must also be included on the request form as there is increasing microbial resistance to beta-lactam antibiotic alternatives.

Blood cultures and other clinical specimens (as indicated) should be taken prior to the commencement of antibiotic treatment.

Systemically ill patients should commence broad spectrum, intravenous antibiotics (within 1 hour of recognition of severe sepsis).

Women, who are suspected of or diagnosed as having an infection, should receive antibiotic treatment specific to their infection when known.

Selection of appropriate antibiotic treatment is complex. Consult an infectious diseases (ID) specialist if there is any uncertainty.

Penicillin hypersensitivity reported by a woman requires critical evaluation as beta-lactam antibiotics are frequently the drug of choice during the perinatal period.

Use of the beta-lactam allergy assessment tool (Reproduced with permission from eTG complete [Internet]. Melbourne, Therapeutic Guidelines Limited; 2019) to determine whether penicillins are not recommended but cephalosporins are safe versus both penicillins and cephalosporins not recommended is essential to determine the most appropriate antibiotic in the context of self-reported beta-lactam allergy.

Perinatal service providers need to ensure cultural appropriateness and sensitivity within a non-judgemental environment when planning care for the Aboriginal woman. All Aboriginal women should be offered and/or referred to cultural support through an Aboriginal healthcare worker or Aboriginal Liaison Officer.

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>g</td>
<td>Gram</td>
</tr>
<tr>
<td>GBS</td>
<td>Group B Streptococcus</td>
</tr>
<tr>
<td>IBW</td>
<td>Ideal body weight</td>
</tr>
<tr>
<td>ID</td>
<td>Infectious Diseases</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>kg</td>
<td>Kilogram</td>
</tr>
<tr>
<td>LSCS</td>
<td>Lower segment caesarean section</td>
</tr>
<tr>
<td>mg</td>
<td>Milligram</td>
</tr>
<tr>
<td>PROM</td>
<td>Prelabour rupture of membranes</td>
</tr>
<tr>
<td>PPROM</td>
<td>Preterm Prelabour Rupture of the Membranes</td>
</tr>
<tr>
<td>ROM</td>
<td>Rupture of membranes</td>
</tr>
</tbody>
</table>
Definitions

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergy</td>
<td>Allergy occurs when a person’s immune system reacts to substances in the environment that are harmless for most people.</td>
</tr>
<tr>
<td>Antibiotic Prophylaxis</td>
<td>The use of antibiotics to prevent infections</td>
</tr>
<tr>
<td>Beta-lactam allergy</td>
<td>Includes allergy to penicillin derivatives (penams), cephalosporins (cephems), monobactams or carbapenems</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Presence of both infection (invasion of tissue, fluid or a body cavity by pathogenic micro-organisms) and systemic manifestations of inflammatory response syndrome (SIRS)</td>
</tr>
<tr>
<td>Severe Allergy</td>
<td>Immediate hypersensitivity involving the development of urticaria, angioedema, bronchospasm or anaphylaxis within one to two hours of drug administration, or Delayed severe hypersensitivity (e.g. severe cutaneous adverse reaction or significant organ involvement such as acute interstitial nephritis)</td>
</tr>
</tbody>
</table>

Prophylactic Antibiotic Use in the Peripartum Period

**Group B Streptococcus (Intrapartum prophylaxis)**

**Indications:**
- Woman screened Group B Streptococcus (GBS) positive during pregnancy
- Previous GBS neonatal sepsis
- Woman GBS negative or unknown with rupture of membranes (ROM) > 18 hours
- Women in preterm labour or with PPROM who are GBS positive or unknown

For more information see the *Early Onset Neonatal Sepsis PPG* available at [www.sahealth.sa.gov.au/perinatal](http://www.sahealth.sa.gov.au/perinatal)

**Practice Considerations:**
- Women who are GBS positive with intact membranes at the time of elective caesarean section do not require antibiotics.
- GBS resistance to clindamycin has increased to approximately 30%¹. For women with penicillin and cephalosporin allergy, “Culture and sensitivity” must also be included on the laboratory request form along with “penicillin and cephalosporin allergy”. If the results demonstrate resistance to clindamycin, prophylaxis with vancomycin is required².

**Recommended antibiotic treatment in labour:**
- Benzylpenicillin 3 g IV loading dose, then 1.8 g IV every 4 hours until birth

*For instructions for preparation and reconstitution of 1.8g dose, see Appendix 2 | Reconstituting BenzylPenicillin*

- Penicillins not recommended but cephalosporins safe (see beta-lactam allergy assessment tool)
- Cefazolin 2 g IV every 8 hours until birth
- Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)
- Clindamycin 600 mg IV every 8 hours until birth providing susceptible isolate

Or
- If the GBS isolate is resistant to clindamycin or GBS susceptibility/sensitivity is unknown, replace clindamycin with Vancomycin 25 mg/kg (based on actual body weight max 3g) IV as a loading dose (refer to **SA Health vancomycin monitoring guideline** for subsequent dosing) until birth³
Caesarean Section

**Indications:**
Woman undergoing both elective and emergency caesarean section

**Practice Considerations:**
Single dose prophylactic antibiotic cover should be administered to all women having a caesarean section. The optimal timing for the administration of prophylactic antibiotics is before skin incision.

**Recommended antibiotic treatment:**
Cefazolin 2 g as a single IV dose (Consider increased dose of cefazolin (3g) if patient is obese (>120kg). Consult ID for advice). For patients colonised with MRSA or at increased risk of being colonised with MRSA, add vancomycin (1gram IV, or 1.5grams IV if >80kg actual body weight).

Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)
Clindamycin 600 mg as a single IV dose (for patients colonised with MRSA or at increased risk of being colonised with MRSA, replace Clindamycin with Vancomycin)
AND
Gentamicin 2 mg/kg as a single IV dose (see gentamicin dosing)

Instrumental Vaginal Birth

**Indications:**
Woman requiring assistance with vaginal birth, either by use of forceps or vacuum

**Practice Considerations:**
Single dose prophylactic antibiotic cover should be considered for all women having an instrumental vaginal birth. The optimal timing for the administration of prophylactic antibiotics is as soon as possible following the birth, within 6 hours.

The use of prophylactic antibiotics following instrumental birth is associated with a reduction in perineal pain, use of pain relief for perineal pain, need for additional perineal care and, wound break down.

**Recommended antibiotic treatment:**
Amoxicillin 1gram and Clavulanic Acid 200mg as a single IV dose
For women without IV access, a single oral dose of Oral Augmentin Duo Forte® (amoxicillin/clavulanic acid 875mg/125 mg) may be given

Penicillins not recommended but cephalosporins safe (see beta-lactam allergy assessment tool)
Cefazolin 2g as a single IV dose AND
Metronidazole 500mg IV

Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)
Clindamycin 600 mg as a single IV dose AND
Gentamicin 2mg/kg IV
Manual Removal of the Placenta

**Indications:**
Manual removal of the placenta

**Practice Considerations:**
Manual removal of the placenta is associated with an increased rate of postpartum endometritis. Despite this, there is no evidence to suggest routine antibiotic use following manual removal of the placenta is beneficial. However, single dose prophylaxis is current practice. If possible, prophylactic antibiotics should be given 30 minutes before starting the procedure.

**Recommended antibiotic treatment:**
Amoxicillin 1gram and Clavulanic Acid 200mg as a single IV dose
For women without IV access, a single oral dose of Oral Augmentin Duo Forte® (amoxicillin/clavulanic acid 875mg/125 mg) may be given

Penicillins not recommended but cephalosporins safe (see beta-lactam allergy assessment tool)

Cefazolin 2g as a single IV dose AND
Metronidazole 500mg IV

Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)

Clindamycin 600 mg as a single IV dose AND
Gentamicin 2mg/kg IV

3rd or 4th degree perineal tears

**Indications:**
3rd or 4th degree perineal lacerations

**Practice Considerations:**
There are no randomised controlled studies comparing antibiotics with placebo for prevention of infection in 3rd or 4th degree perineal tears. Infection carries a high risk of breakdown of the repair resulting in anal incontinence and fistula formation. Therefore, broad-spectrum antibiotics are recommended during and after the repair.

**Recommended antibiotic treatment at time of repair:**
Cefazolin 2 g as a single IV dose (Consider increased dose of cefazolin (3g) if patient is obese (>120kg)).
AND
Metronidazole 500 mg as a single IV dose

Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)

Clindamycin 600 mg as a single IV dose

**Recommended postnatal antibiotic treatment:**
Oral Augmentin Duo Forte® (amoxicillin/clavulanic acid 875mg/125 mg) 12 hourly with food for 5 days

Penicillins not recommended but cephalosporins safe (see beta-lactam allergy assessment tool)

Oral cefalexin 500 mg every 6 hours AND
Oral metronidazole 400 mg every 12 hours for 5 days
Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)
Trimethoprim/sulfamethoxazole 160/800mg 12 hourly for 5 days
AND
Metronidazole 400mg 12 hourly for 5 days

Endocarditis Prophylaxis in Women with Cardiac Disease

Indications:
Specific endocarditis prophylaxis is indicated for women with high-risk cardiac condition AND undergoing a high-risk procedure/situation

High risk cardiac conditions:
- Prosthetic cardiac valve (including bioprosthetic valves and transcatheter-implanted valves)
- Prosthetic material used for cardiac valve repair
- Previous infective endocarditis
- Congenital heart disease, but only if it involves:
  - unrepaired cyanotic defects, including palliative shunts and conduits
  - completely repaired defects with prosthetic material or devices, during the first 6 months after the procedure
  - repaired defects with residual defects at or adjacent to the site of a prosthetic patch or device (which inhibit endothelialisation)
- Cardiac transplantation with the subsequent development of cardiac valvulopathy
- Rheumatic heart disease in all populations

High-risk obstetric procedures/situations:
- Any operative procedure where routine antibiotic prophylaxis is given
- Any operative procedure involving a site with established infection
- Vaginal birth complicated by chorioamnionitis (suspected or proven)
- Vaginal birth complicated by PROM

Non-obstetric procedures/situations are outside the scope of these guidelines, seek expert advice

Recommended antibiotic treatment:
If the prophylactic or treatment antibiotic regimen already includes benzylpenicillin, amoxicillin, amoxicillin-clavulanic acid (Augmentin), piperacillin-tazobactam (Tazocin) or vancomycin then no additional antibiotics are necessary. Ensure a dose is given within 60 minutes prior to procedure (if procedure occurring) or as close as possible to time of birth (if vaginal birth).

If specific additional prophylaxis is necessary:
Add amoxicillin 2 g as a single IV dose as close as practical to the time of birth (or within 60 minutes prior to procedure). Repeat dose after 8 hours if birth has not occurred

Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)
Add vancomycin 1 g (1.5 g > actual body weight 80 kg) IV, administered slowly (over at least one hour) and repeated after 12 hours if birth has not occurred
Prelabour Rupture of Membranes ≥ 37 weeks (PROM)

Women who are known GBS positive should commence GBS Prophylaxis. Women who are GBS negative or unknown should commence GBS prophylaxis once membranes have been ruptured for 18 hours or more.


Preterm Prelabour Rupture of Membranes (PPROM)

Use of prophylactic antibiotics for women with preterm rupture of the membranes is associated with prolongation of pregnancy and improvements in a number of short-term neonatal morbidities, but no significant reduction in perinatal mortality. However, antibiotic prophylaxis is recommended for women with PPROM.

PPROM with no evidence of chorioamnionitis

Recommended antibiotic treatment:
Amoxicillin 2g IV every 6 hours for 48 hours THEN oral Amoxicillin 250mg 3 times per day for a total of 7 days (combined IV and oral)
AND
Oral Erythromycin 250 mg 4 times a day for a maximum of 7-10 days or until birth if this occurs sooner

Note: At onset of established labour, cease Amoxicillin and Erythromycin and commence Group B Streptococcus (Intrapartum prophylaxis). Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool). Oral Erythromycin monotherapy 250mg 4 times a day for 10 days

PPROM with evidence of chorioamnionitis

Recommended antibiotic treatment:
See treatment of chorioamnionitis below.
Note: The addition of alternative antibiotics should be based on the initial and subsequent weekly high vaginal swab results (in consultation with an ID consultant as indicated).

Preterm Labour

Women in active labour AND without symptoms/signs of infection should receive GBS prophylaxis if GBS positive or unknown.

Women should not routinely receive broad spectrum antibiotics in this situation (see Early Onset Neonatal Sepsis and Preterm Labour PPGs at www.sahealth.sa.gov.au/perinatal).
Antibiotic Treatment of Infection

Chorioamnionitis

Indications:
Clinical suspicion of chorioamnionitis
Refer to Sepsis in Pregnancy PPG available at www.sahealth.sa.gov.au/perinatal

Practice Considerations:
The diagnosis of chorioamnionitis relies on the clinical presentation and may be difficult in its early manifestations.
If chorioamnionitis is confirmed, birth of the fetus is indicated.
Do not inhibit labour, but consider hastening birth under intravenous antibiotic cover.
Histological examination of placenta and membranes with evidence of acute inflammation may confirm diagnosis post birth.

Recommended antibiotic treatment until birth:
Amoxicillin 2 g IV every 6 hours AND
Gentamicin 5 mg/kg IV once a day (initial maximum 480 mg, see gentamicin dosing) AND
Metronidazole 500 mg IV every 12 hours
Penicillins not recommended but cephalosporins safe (see beta-lactam allergy assessment tool)
Cefazolin 2 g IV every 8 hours for 48 hours (Note: No cover for enterococcus and listeria provided by cefazolin) AND
Gentamicin 5 mg/kg IV once a day (initial maximum 480 mg, see gentamicin dosing) AND
Metronidazole 500 mg IV every 12 hours
Penicillins and cephalosporins not recommended (see beta-lactam allergy assessment tool)
Clindamycin 600 mg IV every 8 hours AND
Gentamicin 5 mg/kg IV once a day (initial maximum 480 mg, see gentamicin dosing)
Note: if the GBS isolate is resistant to clindamycin or GBS susceptibility/sensitivity is unknown, replace clindamycin with,
Vancomycin 25 mg/kg (based on actual body weight max 3g) IV as a loading dose (refer to SA Health vancomycin monitoring guideline for subsequent dosing)³,14

Recommended continuation of postnatal antibiotic treatment:
Vaginal Birth
If there are no features of sepsis, cease antibiotic therapy following birth as the risk of postpartum endometritis is low³.

Caesarean Birth
If there are no features of sepsis, give one additional IV dose of each of the antibiotics commenced pre-operatively and then cease.
Consider continuing IV antibiotics for up to 24 hours following the caesarean if the woman is at increased risk of postpartum endometritis (e.g. PROM, obese women)³.
Endometritis

Indications:
Systemically ill patients should commence broad spectrum, intravenous antibiotics (within 1 hour of recognition of severe sepsis)\(^2\).
Abdominal pain, fever (> 38°C), tachypnoea and sustained tachycardia (> 90 beats per minute) are indications for admission and intravenous antibiotics.

Practice Considerations:
Common symptoms of endometritis include abdominal pain, uterine tenderness and offensive lochia. The uterus may be subinvolved and slightly soft, with endometritis a cause of secondary postpartum haemorrhage.
In women with fever but no offensive lochia or uterine tenderness, other sources of infection should be considered.
Women with non-severe endometritis (infection is localised, woman is afebrile without systemic symptoms), only require oral antibiotic treatment\(^3\).
Women with severe endometritis (systemic features of infection), require IV antibiotic therapy.
For women with uncomplicated endometritis, cease antibiotics 24-48 hours following resolution of symptoms. Oral step-down is not required\(^3\).
For women with complicated infection (e.g. bacteraemia), IV therapy may be required for longer with oral step-down once clinically stable with normalising inflammatory markers\(^3\).
Consider modifying the therapy based on culture and susceptibility testing (when available) and clinical response.
Consult ID specialist after 72 hours if IV antibiotic therapy still required.

Recommended Antibiotic Treatment:
**IV**
Amoxicillin 2g IV every 6 hours AND
Gentamicin IV 5 mg/kg once each day (initial maximum 480 mg, see [gentamicin dosing](#)) AND
Metronidazole 500 mg IV every 12 hours

Penicillins not recommended but cephalosporins safe (see [beta-lactam allergy assessment tool](#))
Cefazolin 2 g IV every 8 hours for 48 hours (Note: No cover for enterococcus and listeria provided by cefazolin) AND
Gentamicin 5 mg/kg IV once a day (initial maximum 480 mg, see [gentamicin dosing](#)) AND
Metronidazole 500 mg IV every 12 hours

Penicillins and cephalosporins not recommended (see [beta-lactam allergy assessment tool](#))
Clindamycin 600 mg IV every 8 hours AND
Gentamicin 5 mg/kg IV once a day (initial maximum 480 mg, see [gentamicin dosing](#))
Note: If the GBS isolate is resistant to clindamycin or GBS susceptibility/sensitivity is unknown, replace clindamycin with,
Vancomycin 25 mg/kg (based on actual body weight max 3g) IV as a loading dose (refer to [SA Health vancomycin monitoring guideline](#) for subsequent dosing) AND
Metronidazole 500 mg IV every 12 hours

**Oral**
Total duration of therapy (total IV and oral) 7 days
Oral Augmentin Duo Forte® (amoxicillin/clavulanic acid 875mg/125 mg) 12 hourly with food

Penicillins and cephalosporins not recommended (see [beta-lactam allergy assessment tool](#))
Trimethoprim/sulfamethoxazole (160mg/800mg) every 12 hours AND
Metronidazole 400mg every 12 hours
Mastitis

**Indications:**
Evidence of mastitis with systemic symptoms

**Practice Considerations:**
In the absence of systemic symptoms, adequate drainage of the affected area in the breast via infant suckling, breast expression and massage may prevent progression. If the woman shows signs of infection, early treatment with oral antibiotics is important to prevent abscess formation. In women with cellulitis, breast abscess or not improving after 48 hours of oral treatment, admission and treatment with IV antibiotics is indicated.

**Recommended Antibiotic Treatment**

**Oral**
Flucloxacillin 500 mg orally, every 6 hours for at least 5 days
Penicillins not recommended but cephalosporins safe (see [beta-lactam allergy assessment tool](#))
Cefalexin 500 mg orally, every 6 hours for at least 5 days
Penicillins and cephalosporins not recommended (see [beta-lactam allergy assessment tool](#))
Clindamycin 450 mg orally, every 8 hours for at least 5 days

**IV**
Flucloxacillin 2 g IV every 6 hours
Penicillins not recommended but cephalosporins safe (see [beta-lactam allergy assessment tool](#))
Cefazolin 2 g IV every 8 hours
Penicillins and cephalosporins not recommended (see [beta-lactam allergy assessment tool](#))
Vancomycin 25 mg/kg (based on actual body weight max 3g) IV as a loading dose (refer to [SA Health vancomycin monitoring guideline](#)) for subsequent dosing
OR
Clindamycin 600 mg IV every 8 hours

*If patient is known to be colonised with MRSA and has mastitis with systemic features, consider adding Vancomycin to IV Flucloxacillin or Cefazolin*
Vancomycin 25 mg/kg (based on actual body weight max 3g) IV as a loading dose (refer to [SA Health vancomycin monitoring guideline](#)) for subsequent dosing

**Bacterial Vaginosis**
Antibiotic treatment for bacterial vaginosis does not reduce the risk of preterm birth before 37+0 weeks or the risk of preterm prelabour rupture of the membranes. For women undergoing cervical cerclage, consider antibiotic treatment for bacterial vaginosis (See [Cervical Insufficiency and Cerclage PPG available at](#) [www.sahealth.sa.gov.au/perinatal](https://www.sahealth.sa.gov.au/perinatal))

**Recommended antibiotic treatment:**

**Oral**
Clindamycin 300 mg every 12 hours for 7 days OR alternatively if the woman is before 20 weeks’ gestation
Clindamycin 2% vaginal cream, 1 applicatorful at bedtime for 7 nights

**Clindamycin not suitable**

**Oral**
Metronidazole 400 mg every 12 hours for 7 days OR alternatively if the woman is before 20 weeks’ gestation
Metronidazole 0.75% vaginal gel, 1 applicatorful at bedtime for 5 nights
Sepsis where source is unknown

Indications:
Systemically ill patients should commence broad spectrum, intravenous antibiotics (within 1 hour of recognition of severe sepsis)\textsuperscript{1,15}.
Abdominal pain, fever (> 38°C), tachypnoea and sustained tachycardia (> 90 beats per minute) are indications for admission and IV antibiotics\textsuperscript{14}.
Refer to Sepsis in Pregnancy PPG available at www.sahealth.sa.gov.au/perinatal

Practice Considerations:
Consult early with microbiologist or ID specialist for women with evidence of systemic infection.
The choice of antibiotic depends on the clinical suspicion, local flora and culture information. If genital tract sepsis is suspected, prompt early treatment with a combination of high-dose broad-spectrum intravenous antibiotics may be lifesaving\textsuperscript{2}.
Empirical treatment should include broad spectrum antimicrobials active against Gram-negative bacteria, and capable of preventing exotoxin production from Gram-positive bacteria (according to local microbiology policy). Gram-positive cover is necessary if the likelihood of this infection is high\textsuperscript{15}.
Refer to the principles of managing sepsis and septic shock in the e-Therapeutic Guidelines\textsuperscript{3}.

Urinary Tract Infection
Detailed antibiotic information based on organism and clinical presentation is in the Urinary Tract Infections in Pregnancy PPG (see A-Z listing at www.sahealth.sa.gov.au/perinatal)
Gentamicin use and dosing

Gentamicin dosing frequency is generally once daily except for women with abnormal renal function, where the initial dose should be given once and advice obtained from Infectious Diseases regarding dosing frequency.

Pregnant women should be dosed according to actual body weight as there are a number of pharmacokinetic changes, such as increased volume of distribution and renal clearance that could result in sub-therapeutic dosing if Ideal Body Weight (IBW) is used. However, caution should be used in overweight/obese women (pre-pregnancy BMI > 25) where dosing should be based on IBW:

- Female Ideal Body Weight = 45.5 kg + 0.9 kg (for each cm over 152 cm)
- Initial starting doses should be capped accordingly, unless otherwise advised by an ID specialist.
- Women aged 16-60 years: 5 mg/kg dose (maximum of 480 mg)

Monitoring gentamicin levels

In the absence of a history of renal disease, short term treatment (2-3 days) with Gentamicin does not require levels.

If levels are required, available evidence suggests the area under the curve (AUC) of plasma aminoglycoside concentration versus time may be a better predictor of toxicity and efficacy than the traditional peak and trough monitoring.

Two blood samples taken at one hour and six hours after the first dose are required to calculate the AUC from these 2 plasma concentrations and dosage modifications recommended as necessary.

- It is important to record the exact time the dose was given and the exact time of taking the blood samples on the request forms / collection tubes.

Repeat levels are not usually required unless treatment is prolonged, in which case they should be done after 5-7 days. Potential efficacy or toxicity concerns may require earlier repeat levels.

For further information refer to SA Health Policy - Aminoglycoside: Recommendations for Use, Dosing and Monitoring Clinical Guideline.
References


2. Surviving Sepsis Campaign available at http://www.survivingsepsis.org


Useful Websites:


Australian e-Therapeutic Guidelines Complete: Antibiotic: https://tgldcdp.tg.org.au
Suggested management of patients reporting hypersensitivity to penicillins in whom a beta-lactam antibiotic is the preferred drug

Penicillin hypersensitivity reported by a patient in whom a beta-lactam antibiotic is the preferred drug

History of immediate (IgE-mediated) penicillin hypersensitivity (typically occurs within 1 to 2 hours of drug exposure)
- Immediate severe penicillin hypersensitivity (e.g., extensive urticaria, compromised airway, angioedema, hypotension, collapse or anaphylaxis)
  - Avoid penicillins and cephalosporins [NB1].
  - Safe to administer a non-beta-lactam antibiotic or aztreonam.
  - Can consider a carbapenem [NB2].
- Immediate nonsevere penicillin hypersensitivity (e.g., mild urticaria or immediate rash)
  - Avoid penicillins. Safe to administer most cephalosporins. Avoid cefalexin and cefaclor in patients with amoxicillin or ampicillin allergy.
  - Avoid cefazolin and cephalosporins [NB4].
  - Safe to administer a non-beta-lactam antibiotic or aztreonam.
  - Can consider a carbapenem [NB2].

If a penicillin is essential, perform desensitisation. In a non-urgent situation, consider specific allergy testing and drug provocation under specialist supervision (where such testing is available).

History of delayed (T-cell mediated) penicillin hypersensitivity (typically occurs days after starting treatment, but can occur more rapidly on rechallenge)
- Delayed severe penicillin hypersensitivity (e.g., severe cutaneous adverse reaction [NB3] or significant organ involvement such as acute interstitial nephritis)
  - Avoid penicillins and cephalosporins [NB4].
  - Safe to administer a non-beta-lactam antibiotic or aztreonam.
  - Can consider a carbapenem [NB2].
  - Avoid desensitisation in patients with a history of delayed severe hypersensitivity because further drug exposure can be fatal.
- Delayed nonsevere penicillin hypersensitivity (usually a maculopapular rash or benign childhood rash; not a severe cutaneous adverse reaction [NB3] and no significant organ involvement)
  - Avoid penicillins. However, in a non-urgent situation and under specialist guidance, consider a single dose of a penicillin followed by a prolonged (5 to 7 day) provocation test.
  - Safe to administer a cephalosporin in patients with a history of a mild reaction or a reaction that occurred in the distant past [NB5].
  - Safe to administer a carbapenem or aztreonam.

History of penicillin AND cephalosporin immune-mediated hypersensitivity
- Avoid all beta lactams, except for aztreonam [NB6].

History of non-immune-mediated adverse effect (e.g., gastrointestinal intolerance)
- Safe to administer any beta lactam.

Avoid all cephalosporins. Refer to specialised antibiotic allergy testing centre.

Remove penicillin allergy from the patient’s medical record or annotate the true nature of the reaction.

Penicillins include: phenoxymethylpenicillin, benzylpenicillin, amoxicillin, ampicillin, dicloxacillin, flucloxacillin, piperacillin

Cephalosporins include: cefalexin, cefuroxime, cefaclor, cefazolin, cefotaxin, ceftriaxone, cefotaxime, cefetaxime, cefepime

Carbapenems include: imipenem, meropenem, ertapenem

NB1: In a critical situation, a cephalosporin can be considered in the group after undertaking a risk-benefit analysis and assessment of potential side chain cross-reactivity. Seek expert advice.

NB2: For example DRESS, SJS/TEN, AGER.

NB3: There is limited evidence on the safety of cephalosporins in patients with a history of penicillin associated acute interstitial nephritis (AIN). In a critical situation, directed therapy with a cephalosporin can be considered.

NB4: In patients who have had a recent reaction, consider avoiding cephalosporins with the same or similar R1 side-chain as the implicated penicillin.

NB5: However, avoid aztreonam in patients hypersensitive to ceftazidime; these drugs have the same R1 side-chain, so there is a risk of cross-reactivity.

Therapeutic Guidelines Limited (www.tg.org.au) is an independent not-for-profit organisation dedicated to deriving guidelines for therapy from the latest world literature, interpreted and distilled by Australia’s most eminent and respected experts.

Published in eTG complete, April 2019. ©Therapeutic Guidelines Ltd
Appendix 2 | Reconstituting BenzylPenicillin

BenzylPenicillin 1.8gram dosage reconstituting instructions

**EITHER:**

Using **3 X 600mg vial** benzylpenicillin:
- Reconstitute each vial with 10mL of water for injection. Do this with 3 vials.
- Add the reconstituted vials to 100mL bag of Normal Saline (or compatible fluid) and administer over 30minutes*
* Fluid restricted patients, **1.8grams can be diluted to a minimum of 30mL compatible fluid (60mg/mL)**

**OR:**

Using **3gram vial** benzylpenicillin:
- Add 13mLs of water for injection to 3 gram vial of benzylpenicillin to make a total volume of 15ml (200mg per mL)
- Draw up 9mLs (1.8grams) and add to 100ml bag of Normal Saline (or compatible fluid) and administer over 30minutes
- Discard the remaining 6mLs
* For fluid restricted patients, **1.8grams can be diluted to a minimum of 30mL compatible fluid (60mg/mL)**

N.B Benzylpenicillin 3 gram vial powder volume is 2 mL

**OR:**

Using **1.2gram vial** PLUS **600mg vial**
- Reconstitute 1.2 gram vial with 10mL of water for injection
- Reconstitute 600mg vial with 10mL of water for injection
- Add the two reconstituted vials to 100mL bag of Normal Saline (or compatible fluid) and administer over 30minutes*
* Fluid restricted patients, **1.8grams can be diluted to a minimum of 30mL compatible fluid (60mg/mL)**
Acknowledgements

The South Australian Perinatal Practice Guidelines gratefully acknowledge the contribution of clinicians and other stakeholders who participated throughout the guideline development process particularly:

Write Group Members
Dr Rory Hannah  
Catherine Leggett  
Dr Celia Cooper  
Dr Stefan Lammerink  
Dr Brett Ritchie  
Rebecca Smith  
Dr Nan Vasilunas  
Dr Michael McEvoy  
Dr Elizabeth Beare  
Dr Sue Kennedy-Andrews  
Dr Anthia Rallis  
Marnie Aldred  
Tanja Gustafsson  
Dr Anupam Parange

Other Major Contributors
Dr Yumin Chan  
Sarah Conolan  
A/Prof Rosalie Grivell  
Dr Mark Morton

SAPPG Management Group Members
Sonia Angus  
Lyn Bastian  
Dr Elizabeth Beare  
Elizabeth Bennett  
Dr Feisal Chenia  
John Coombas  
Dr Danielle Crosby  
Dr Scott Morris  
Dr Ray Farley  
Allison Waldron  
Dr Charlotte Taylor  
Rosina Gergis  
Dr Anupam Parange  
Marnie Aldred  
Dr Michael McEvoy
Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: HealthCYWHSPerinatalProtocol@sa.gov.au
Endorsed by: Domain Custodian, Clinical Governance, Safety and Quality
Next review due: 20/12/2027
ISBN number: 978-1-76083-487-6
PDS reference: PPG020
Policy history: Is this a new policy (V1)? N
Does this policy amend or update and existing policy? Y
If so, which version? V8.0
Does this policy replace another policy with a different title? N
If so, which policy (title)?

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>29/06/2022</td>
<td>V9</td>
<td>Domain Custodian, Clinical Governance, Safety and Quality</td>
<td>Complete review to align with updated evidence</td>
</tr>
<tr>
<td>20/12/2019</td>
<td>V8</td>
<td>SA Health Commissioning and Performance Unit</td>
<td>Formally reviewed in line with 3 year scheduled timeline for review.</td>
</tr>
<tr>
<td>07/09/2015</td>
<td>V7</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Minor update</td>
</tr>
<tr>
<td>25/03/2014</td>
<td>V6</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Minor update</td>
</tr>
<tr>
<td>20/05/2013</td>
<td>V5</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Formally reviewed in line with 3 year scheduled timeline for review.</td>
</tr>
<tr>
<td>14/09/2010</td>
<td>V4</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Minor update</td>
</tr>
<tr>
<td>23/08/2010</td>
<td>V3</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Minor update</td>
</tr>
<tr>
<td>21/04/2009</td>
<td>V2</td>
<td>SA Maternal and Neonatal Clinical Network</td>
<td>Formally reviewed in line with 3 year scheduled timeline for review.</td>
</tr>
</tbody>
</table>